The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Source:
Recombinant SARS-Cov-2 N protein (EG.5/BA.4/BA.4.6)(P13L,DEL31-33,R203K,G204R,S413R)is expressed in E.coli with N-His. It contains the amino acid sequence of 1-419/419
Expression System:
E.coli
Purity:
> 90% as determined by SDS- PAGE
* VAT and and shipping costs not included. Errors and price changes excepted
